Key words: Metabolomics, Xinnaoxin tablet, Coronary heart disease, Keap1-Nrf2/HO-1, Biomarker
SHXD;UPLC-PDA;MS, PBMC, Nature killer cells, anti-inflammatory, Cell phenotype antibody